Navigation Links
Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
Date:8/6/2009

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and treasurer. Mr. Driscoll will report to Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer.

Previously Mr. Driscoll served as Chief Financial Officer, and President and Chief Executive Officer of Genelabs Technologies, Inc. Prior to his position at Genelabs, Mr. Driscoll served in a variety of financial and senior management positions at Astraris, Inc., OXiGENE, Inc. and Collagenesis Corp. He also spent more than twenty years with Instrumentation Laboratory as vice president of finance for the Americas.

Dr. Singhvi stated: "We are pleased to welcome Fred Driscoll to Novavax as our new chief financial officer. Fred is joining Novavax at a time of significant growth and his contribution at such a critical juncture will be welcome by everyone on our Executive Team. We are looking forward to tapping into his many years of biotechnology industry experience as we expand our vaccine development programs, manufacturing operations and international collaborations."

Mr. Michael A. McManus, Jr., Novavax's Audit Committee Chairman, commented: "Mr. Driscoll is a seasoned and talented executive with valuable experience in financial management, corporate strategy and fundraising, and investor relations. Fred has had considerable experience as a public company CFO and has raised significant funds in the capital markets. In addition, he enjoys a strong reputation in the investment community. We welcome him to our Executive team."

Mr. Driscoll received his bachelor's degree in accounting from Bentley College.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
2. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
3. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
4. Novavax Announces Repayment of $5 Million of Convertible Debt
5. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
6. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
7. Novavax Appoints Stanley Erck to Board of Directors
8. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
9. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
10. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
11. Novavax Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
Breaking Biology News(10 mins):